Columbus Hill Capital Management L.P. Increases Stake in Surgery Partners, Inc. (NASDAQ:SGRY)

Columbus Hill Capital Management L.P. raised its stake in Surgery Partners, Inc. (NASDAQ:SGRY) by 39.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 541,046 shares of the company’s stock after acquiring an additional 153,654 shares during the quarter. Surgery Partners makes up approximately 2.6% of Columbus Hill Capital Management L.P.’s investment portfolio, making the stock its 17th largest position. Columbus Hill Capital Management L.P. owned approximately 0.43% of Surgery Partners worth $12,871,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. DekaBank Deutsche Girozentrale lifted its stake in shares of Surgery Partners by 102.0% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 2,723 shares of the company’s stock valued at $80,000 after purchasing an additional 1,375 shares during the period. EntryPoint Capital LLC raised its position in shares of Surgery Partners by 257.1% in the first quarter. EntryPoint Capital LLC now owns 6,399 shares of the company’s stock worth $191,000 after acquiring an additional 4,607 shares during the period. Capstone Investment Advisors LLC acquired a new position in shares of Surgery Partners in the fourth quarter worth about $211,000. MeadowBrook Investment Advisors LLC boosted its stake in shares of Surgery Partners by 15.9% during the 2nd quarter. MeadowBrook Investment Advisors LLC now owns 12,320 shares of the company’s stock worth $293,000 after acquiring an additional 1,690 shares in the last quarter. Finally, Natixis Advisors LLC grew its position in shares of Surgery Partners by 11.0% during the 2nd quarter. Natixis Advisors LLC now owns 12,452 shares of the company’s stock valued at $296,000 after acquiring an additional 1,237 shares during the period.

Surgery Partners Price Performance

Surgery Partners stock opened at $32.57 on Friday. The company has a fifty day simple moving average of $30.22 and a 200-day simple moving average of $27.58. The firm has a market capitalization of $4.14 billion, a price-to-earnings ratio of 44.87, a PEG ratio of 2.44 and a beta of 2.76. The company has a quick ratio of 1.69, a current ratio of 1.83 and a debt-to-equity ratio of 0.96. Surgery Partners, Inc. has a 52-week low of $22.05 and a 52-week high of $36.92.

Surgery Partners (NASDAQ:SGRY) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.01. The company had revenue of $762.10 million during the quarter, compared to analysts’ expectations of $735.94 million. Surgery Partners had a negative net margin of 1.17% and a positive return on equity of 2.96%. Surgery Partners’s revenue was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.25 EPS. On average, equities analysts anticipate that Surgery Partners, Inc. will post 0.86 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SGRY has been the subject of a number of analyst reports. Macquarie initiated coverage on Surgery Partners in a report on Friday, June 28th. They issued an “outperform” rating and a $31.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $43.00 target price on shares of Surgery Partners in a research note on Monday, August 19th. Benchmark reissued a “buy” rating and issued a $50.00 price target on shares of Surgery Partners in a research note on Monday, August 26th. Citigroup reduced their price objective on shares of Surgery Partners from $38.00 to $36.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $49.00 target price on shares of Surgery Partners in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Surgery Partners presently has a consensus rating of “Moderate Buy” and an average target price of $39.86.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.